News Headlines Article

Day 1: Avastin patients, families protest before FDA hearing
San Francisco Business Times

Genentech Inc. ’s cancer-fighting Avastin is in front of a Food and Drug Administration panel today, a struggle that has inspired breast cancer patients and their families. The hearing — today and Wednesday at the FDA campus in Silver Spring, Md. — will go a long way toward determining if Avastin will win full approval for metastatic breast cancer patients. The drug was conditionally approved in February 2008 on the basis of one study, but the FDA late last year said it would rescind that approval.